New Zealand markets closed
  • NZX 50

    11,112.16
    -28.91 (-0.26%)
     
  • NZD/USD

    0.6172
    +0.0021 (+0.35%)
     
  • ALL ORDS

    6,836.90
    +52.60 (+0.78%)
     
  • OIL

    98.32
    -0.21 (-0.21%)
     
  • GOLD

    1,739.50
    +3.00 (+0.17%)
     

Viral Conjunctivitis Drugs in Development Pipeline Guide 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

·3-min read

DUBLIN, May 19, 2022--(BUSINESS WIRE)--The "Viral Conjunctivitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The pipeline guide provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 6 and 1 respectively.

The pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Report Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).

  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.

  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Key Topics Covered:

Viral Conjunctivitis - Overview

Viral Conjunctivitis - Therapeutics Development

  • Pipeline Overview

  • Pipeline by Companies

  • Products under Development by Companies

Viral Conjunctivitis - Therapeutics Assessment

  • Assessment by Target

  • Assessment by Mechanism of Action

  • Assessment by Route of Administration

  • Assessment by Molecule Type

Viral Conjunctivitis - Companies Involved in Therapeutics Development

  • Invirsa Inc

  • IVIEW Therapeutics Inc

  • Kiora Pharmaceuticals Inc

  • Microbiotix Inc

  • NanoViricides Inc

  • Okogen Inc

  • Plex Pharmaceuticals Inc

  • Starpharma Holdings Ltd

  • TGV-Inhalonix Inc

Viral Conjunctivitis - Drug Profiles

  • astodrimer - Drug Profile

  • EKCCide-I - Drug Profile

  • filociclovir - Drug Profile

  • INV-102 - Drug Profile

  • KIO-101 - Drug Profile

  • Mul-1867 - Drug Profile

  • OKG-0502 - Drug Profile

  • povidone iodine ER - Drug Profile

  • ranpirnase - Drug Profile

Viral Conjunctivitis - Dormant Projects

Viral Conjunctivitis - Discontinued Products

Viral Conjunctivitis - Product Development Milestones

For more information about this report visit https://www.researchandmarkets.com/r/ihtz8b

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220519005532/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting